In a recent study, CD166-specific CAR-T cells were tested in vitro, in MNNG/HOS, U2OS, MG-63 and Saos-2 osteosarcoma cell lines, and in vivo, in NOD/SCID mice, in order to evaluate the capability of CAR-T to selectively target CD166+ cells. This evidence concerns the gene ALCAM and osteosarcoma.